Adjuvant chemotherapy of gastric carcinoma: a pilot study of oral administration of injectable 5-fluorouracil.
During the past three years we have entered 54 patients with gastric adenocarcinoma into a clinical trial of oral administration of injectable 5-fluorouracil (5-Fu). Of the 20 unresectable advanced cases, the median survival was 6.2 months, and for 34 resectable ones, median survival was 22 months. These results were comparable to those reported in the literature. It is also safe, easy to administer, well tolerated, and does not have any apparent side effects. The author discovered for the first time that oral administration of 5-Fu could improve the liver function as manifested by a marked decrease of serum GPT level in advanced gastric cancer.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D008099:Liver / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011788:Quality of Life; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D013997:Time Factors
D005472:Fluorouracil